We serve Chemical Name:(2-hydroxyphenyl)-(1,2-oxazol-4-yl)methanone CAS:53658-17-6 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:(2-hydroxyphenyl)-(1,2-oxazol-4-yl)methanone
CAS.NO:53658-17-6
Synonyms:hms1729c13
Molecular Formula:C10H7NO3
Molecular Weight:189.16700
HS Code:2934999090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:333.3ºC at 760 mmHg
Density:1.332g/cm3
Index of Refraction:1.596
PSA:63.33000
Exact Mass:189.04300
LogP:1.61120
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like hms1729c13 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,hms1729c13 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,hms1729c13 Use and application,hms1729c13 technical grade,usp/ep/jp grade.
Related News: For example, an active ingredient to relieve pain is included in a painkiller. (2-hydroxyphenyl)-(1,2-oxazol-4-yl)methanone manufacturer In the early stage of market development, API companies usually need to strive to become a supply company for pharmaceutical companies after quickly completing product preparations. In the subsequent scale-up of production and market application, the relationship between pharmaceutical companies and API companies will become closer. The choice of R & D products of pharmaceutical companies will also be affected by pharmaceutical companies in turn. (2-hydroxyphenyl)-(1,2-oxazol-4-yl)methanone supplier This leads to low numbers of one or more types of circulating blood cells, and to the need for blood transfusions. In MDS, some of the cells in the bone marrow are abnormal (dysplastic) and may have genetic abnormalities associated with them. (2-hydroxyphenyl)-(1,2-oxazol-4-yl)methanone vendor This decision has shaken the foundations of the scientific process and methods, said Dr. Jason Karlawish, co-director of the Penn Memory Center in Philadelphia. Karlawish ran one of the trial sites for the Biogen drug. (2-hydroxyphenyl)-(1,2-oxazol-4-yl)methanone factory This decision has shaken the foundations of the scientific process and methods, said Dr. Jason Karlawish, co-director of the Penn Memory Center in Philadelphia. Karlawish ran one of the trial sites for the Biogen drug.
